Revenue
2022
2023
2024
2025
Dyne Therapeutics, Inc. (DYN)
Price$18.29Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — |
| Research & development | $398.3M | $281.4M | $210.8M | $142.8M | $121.3M | $45.2M | $11.0M |
| Operating expenses | $468.2M | $343.9M | $242.2M | $171.0M | $150.0M | $58.6M | $13.8M |
| Operating income | −$468.2M | −$343.9M | −$242.2M | −$171.0M | −$150.0M | −$58.6M | −$13.8M |
| EBITDA | −$466.1M | −$342.2M | −$240.5M | −$169.3M | −$148.9M | −$57.9M | −$13.6M |
| Net income | −$446.2M | −$317.4M | −$235.9M | −$168.1M | −$149.3M | −$59.4M | −$14.9M |
| Basic EPSper basic share | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | -$6.08 |
| Diluted EPSper diluted share | -$3.47 | -$3.37 | -$3.95 | -$3.23 | -$2.93 | -$4.13 | -$6.08 |
Owners
Reported shareholders
18.66%of listed shares
T. Rowe Price Investment Management, Inc.30.91M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
T. Rowe Price Investment Management, Inc. | 18.66%30.91M shares |
BlackRock, Inc. | 7.49%12.4M shares |
Jupiter Topco LLC | 7.24%12M shares |
FMR LLC | 6.76%11.21M shares |
STATE STREET CORP | 4.50%7.46M shares |
Orbis Allan Gray Ltd | 4.23%7.01M shares |
Rhodes Jason P | ≈4.11%6.81M shares |
Atlas Venture Life Science Advisors, LLC | 4.10%6.8M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.81%6.31M shares |
TCG Crossover Management, LLC | 2.79%4.62M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.44%4.05M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.38%3.94M shares |
Kersten Dirk | ≈2.32%3.85M shares |
FCPM III SERVICES B.V. | 2.32%3.85M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.26%3.74M shares |
Vestal Point Capital, LP | 2.04%3.38M shares |
ORBIMED ADVISORS LLC | 1.95%3.24M shares |
Frazier Life Sciences Management, L.P. | 1.90%3.15M shares |
JPMORGAN CHASE & CO | 1.90%3.15M shares |
ARMISTICE CAPITAL, LLC | 1.86%3.09M shares |
Percentages use 165.67M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 40.7K | $21.14 | $860.4K | 975.9K |
| Jun 29, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 51.8K | $21.14 | $1.09M | 1.34M |
| Jun 29, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 103.0K | $21.14 | $2.18M | 4.48M |
| Jun 26, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 64.4K | $21.28 | $1.37M | 1.02M |
| Jun 26, 2026Form 4 · 10b5-1 | Rhodes Jason PDirector | SellCommon Stock · indirect | 81.9K | $21.28 | $1.74M | 1.40M |
Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
